UF1NS100614
Cooperative Agreement
Overview
Grant Description
Validation of Imaging and Blood-Based Small Vessel VCID Biomarkers in Multiethnic Population - Project Summary/Abstract
The MARKVCID Consortium was established in 2016 to pursue the initial stages of multi-site validation of 7 imaging-based and 4 fluid-based candidate biomarkers for small vessel vascular contributions to cognitive impairment and dementia (VCID).
As one of the 7 participating sites, our team at the University of Southern California (USC) has analyzed and optimized candidate VCID biomarkers during the UH2 phase (years 1-2) and participated in the consortium-wide program of biomarker scaling-up, multi-site protocol implementation, and initial multi-site validation during the UH3 phase (years 3-5).
USC has led the consortium-wide development and implementation of the Optical Coherence Tomography Angiography (OCTA) biomarker kit which is based on an FDA-approved device that allows in vivo and completely noninvasive imaging of retinal capillaries with a spatial resolution of ~10 microns.
We have also participated in the validation of the other 6 MRI based candidate biomarkers while contributing blood samples for the validation of the 3 plasma-based candidate biomarkers.
The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of candidate VCID biomarkers in longitudinal studies of diverse populations that are typical in clinical settings in the US.
Capitalizing on the high racial diversity in Los Angeles, we plan to enroll a multiethnic longitudinal cohort of at least 200 subjects that are enriched for small vessel VCID, including 100 Latinx subjects from the Los Angeles Latino Eye Study (LALES), 50 African Americans (AAs) enrolled in the African American Eye Disease Study (AFEDS), and 50 Caucasian participants from the clinical core of the USC ADRC.
We have performed pilot studies in both Latinx and AA subjects (the two largest minority groups in the US) using MARKVCID protocols to show the feasibility of conducting such studies in a multiethnic cohort.
We have also built a multiethnic team of investigators, technical staff, research coordinators, and community outreach staff to streamline enrollment, achieve the recruitment milestones, and perform longitudinal follow-up studies.
Our team includes established expertise, equipment, and infrastructure for OCTA, MRI, fluid biomarker, and clinical/cognitive evaluation of VCID, as well as a proven track record in the sharing of de-identified clinical data through the Laboratory of Neuro Imaging (LONI) for the second phase of MARKVCID project.
The MARKVCID Consortium was established in 2016 to pursue the initial stages of multi-site validation of 7 imaging-based and 4 fluid-based candidate biomarkers for small vessel vascular contributions to cognitive impairment and dementia (VCID).
As one of the 7 participating sites, our team at the University of Southern California (USC) has analyzed and optimized candidate VCID biomarkers during the UH2 phase (years 1-2) and participated in the consortium-wide program of biomarker scaling-up, multi-site protocol implementation, and initial multi-site validation during the UH3 phase (years 3-5).
USC has led the consortium-wide development and implementation of the Optical Coherence Tomography Angiography (OCTA) biomarker kit which is based on an FDA-approved device that allows in vivo and completely noninvasive imaging of retinal capillaries with a spatial resolution of ~10 microns.
We have also participated in the validation of the other 6 MRI based candidate biomarkers while contributing blood samples for the validation of the 3 plasma-based candidate biomarkers.
The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of candidate VCID biomarkers in longitudinal studies of diverse populations that are typical in clinical settings in the US.
Capitalizing on the high racial diversity in Los Angeles, we plan to enroll a multiethnic longitudinal cohort of at least 200 subjects that are enriched for small vessel VCID, including 100 Latinx subjects from the Los Angeles Latino Eye Study (LALES), 50 African Americans (AAs) enrolled in the African American Eye Disease Study (AFEDS), and 50 Caucasian participants from the clinical core of the USC ADRC.
We have performed pilot studies in both Latinx and AA subjects (the two largest minority groups in the US) using MARKVCID protocols to show the feasibility of conducting such studies in a multiethnic cohort.
We have also built a multiethnic team of investigators, technical staff, research coordinators, and community outreach staff to streamline enrollment, achieve the recruitment milestones, and perform longitudinal follow-up studies.
Our team includes established expertise, equipment, and infrastructure for OCTA, MRI, fluid biomarker, and clinical/cognitive evaluation of VCID, as well as a proven track record in the sharing of de-identified clinical data through the Laboratory of Neuro Imaging (LONI) for the second phase of MARKVCID project.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Funding Agency
Place of Performance
Los Angeles,
California
900890110
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have decreased 13% from $2,623,751 to $2,281,972.
University Of Southern California was awarded
Multiethnic Validation of Small Vessel VCID Biomarkers
Cooperative Agreement UF1NS100614
worth $2,281,973
from National Institute on Aging in September 2016 with work to be completed primarily in Los Angeles California United States.
The grant
has a duration of 6 years 10 months and
was awarded through assistance program 93.866 Aging Research.
The Cooperative Agreement was awarded through grant opportunity Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed).
Status
(Complete)
Last Modified 8/20/24
Period of Performance
9/30/16
Start Date
7/31/23
End Date
Funding Split
$2.3M
Federal Obligation
$0.0
Non-Federal Obligation
$2.3M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UF1NS100614
Transaction History
Modifications to UF1NS100614
Additional Detail
Award ID FAIN
UF1NS100614
SAI Number
UF1NS100614-2711390984
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NQ00 NIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Funding Office
75NN00 NIH NATIONAL INSITUTE ON AGING
Awardee UEI
G88KLJR3KYT5
Awardee CAGE
1B729
Performance District
CA-34
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,134,814 | 90% |
| National Institutes of Health Conditional Gift Fund, Health and Human Services (075-8253) | Health care services | Grants, subsidies, and contributions (41.0) | $128,555 | 10% |
Modified: 8/20/24